Efinaconazole
- Generic Name
- Efinaconazole
- Brand Names
- Jublia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22F2N4O
- CAS Number
- 164650-44-6
- Unique Ingredient Identifier
- J82SB7FXWB
- Background
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
- Indication
Indicated in the treatment of fungal infection of the nail, known as onychomycosis.
- Associated Conditions
- Onychomycosis
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
- Conditions
- Mild to Moderate Onychomycosis Due to Dermatophyte
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT03280927
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Western University of Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03168841
- Locations
- 🇺🇸
Western University of Health Sciences, Pomona, California, United States
Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish
- Conditions
- Onychomycosis of Toenail
- Interventions
- Other: Application of Nail Polish
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 13
- Registration Number
- NCT03110029
- Locations
- 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
Study Evaluating the Effect of Jublia on Dermatophytomas
- Conditions
- DermatophytosisOnychomycosis
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 19
- Registration Number
- NCT03098615
- Locations
- 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
Real-World Evaluation of the Effect of Jublia on Nail Polish
- Conditions
- Evaluation of Jublia on Nail Polish With Healthy Toenails
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 5
- Registration Number
- NCT03022916
- Locations
- 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02812771
- Locations
- 🇺🇸
Valeant Site 01, Birmingham, Alabama, United States
🇺🇸Valeant Site 08, Baltimore, Maryland, United States
🇺🇸Valeant Site 06, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Dow Pharmaceutical Sciences
- Target Recruit Count
- 870
- Registration Number
- NCT01008033
- Locations
- 🇺🇸
Temple University School of Podiatric Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
🇺🇸University Clinical Trials, Inc, San Diego, California, United States
The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Dow Pharmaceutical Sciences
- Target Recruit Count
- 780
- Registration Number
- NCT01007708
- Locations
- 🇨🇦
K. Papp Clinical Research, Waterloo, Ontario, Canada
🇨🇦Beatrice Wang, MD, Westmount, Quebec, Canada
🇺🇸South Bend Clinic, South Bend, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.